PCSK9 and Atrial Fibrillation: A New Perspective on an Old Problem

Q: What is the clinical evidence from this study?

Study design: Review. Population: Atrial fibrillation. Intervention: PCSK9 and PCSK9 inhibitors (alirocumab, evolocumab, inclisiran). Primary outcome: Atrial fibrillation incidence, progression, and related cardiovascular events.

Q: What does this research mean for the field?

PCSK9 contributes to atrial fibrillation pathophysiology through inflammatory, oxidative, and structural remodeling pathways, but clinical evidence that PCSK9 inhibitors reduce atrial fibrillation incidence remains preliminary and hypothesis-generating. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Amirhossein Sahebkar; Wael A. Almahmeed; Prashant Kesharwani; Tannaz Jamialahmadi

doi:10.1155/cdr/7328020

January 1, 2026Cardiovascular TherapeuticsOpen Access

PCSK9 and Atrial Fibrillation: A New Perspective on an Old Problem

View Full Paper

Ask AI

Bookmark

Share

Key result

PCSK9 promotes atrial fibrillation remodeling, but clinical benefit from PCSK9 inhibitors remains unproven.

Why the study?

PCSK9 has emerged as a novel contributor to atrial fibrillation pathophysiology, while evidence from randomized controlled trials evaluating PCSK9 inhibitors with AF as a primary clinical endpoint remains limited.

Does PCSK9 inhibition reduce the incidence, progression, or cardiovascular complications of atrial fibrillation in high-risk patients?

Key Points

To review the pathophysiological mechanisms linking PCSK9 to atrial fibrillation and evaluate the potential therapeutic role of PCSK9 inhibitors in preventing and managing this arrhythmia.
Synthesized findings across randomized controlled trials, Mendelian randomization analyses, observational biomarker studies, and experimental mechanistic models.
Assessed clinical outcomes related to PCSK9 monoclonal antibody therapy (alirocumab, evolocumab) and newer agents including inclisiran in patients with elevated cardiovascular risk and dyslipidemia.
A meta-analysis of randomized controlled trials showed that PCSK9 monoclonal antibody therapy was associated with reduced AF (RR 0.84; 95% CI 0.72–0.98), whereas in an RCT of patients with recent ACS and dyslipidemia, alirocumab was not significantly associated with AF incidence (HR 0.91; 95% CI 0.77–1.09).
Mendelian randomization linked genetically predicted PCSK9 suppression to a modest reduction in AF risk (OR 0.92; 95% CI 0.85–0.99), while observational studies identified higher circulating PCSK9 with higher cardiovascular event risk in AF (HR 1.64; 95% CI 1.12–2.41) and high ABI (OR 1.65; 95% CI 1.05–2.60).
Evidence remains hypothesis-generating because dedicated randomized controlled trials evaluating atrial fibrillation as a primary or prespecified clinical endpoint are lacking.

Structured PICO

Does PCSK9 inhibition reduce the incidence, progression, or cardiovascular complications of atrial fibrillation in high-risk patients?

P

Population

Patients with or at elevated cardiovascular risk for atrial fibrillation, including those with dyslipidemia and atherosclerotic cardiovascular disease, discussed across reviewed clinical, genetic, and preclinical studies.

I

Intervention

PCSK9 inhibition (including monoclonal antibodies alirocumab and evolocumab, and small interfering RNA inclisiran) or elevated circulating/genetically predicted PCSK9 levels.

C

Comparator

Placebo, ezetimibe, or lower/suppressed PCSK9 levels across reviewed studies.

O

Outcome

Atrial fibrillation incidence, progression, structural remodeling, and major adverse cardiovascular events (MACE).

This narrative review synthesizes emerging mechanistic and clinical links between PCSK9 and atrial fibrillation, concluding that while PCSK9 pathways are biologically plausible targets, dedicated RCTs with AF as a primary endpoint are needed before using PCSK9 inhibitors for rhythm management.

Limitations

Atrial fibrillation was not a prespecified primary endpoint in most randomized controlled trials of PCSK9 inhibitors.
Differences in event ascertainment, endpoint definitions, and statistical power across included trials limit firm conclusions.
Observational biomarker studies are vulnerable to confounding by systemic inflammation and cardiovascular comorbidities as well as reverse causation.
Mendelian randomization studies depend on the validity of genetic instruments and assumptions regarding the absence of horizontal pleiotropy.
Mechanistic and animal model findings have uncertain direct applicability to heterogeneous human atrial fibrillation phenotypes.
AF was not a primary clinical endpoint in most randomized controlled trials of PCSK9 inhibitors
Differences in AF event ascertainment, adjudication, and endpoint definitions across trials
Observational studies are subject to confounding and reverse causation from underlying inflammation, metabolic dysfunction, and comorbidities
Mendelian randomization studies rely on assumptions regarding genetic instruments and absence of horizontal pleiotropy
Preclinical animal models (e.g., rat rheumatoid arthritis model) may not fully extrapolate to heterogeneous human AF

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Does not support PCSK9 inhibitor use for AF management; leaves open the need for dedicated RCTs with primary arrhythmic endpoints.

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel contributor to atrial fibrillation (AF) pathophysiology. Recent studies suggest that elevated PCSK9 levels may promote AF through multiple mechanisms, including platelet activation, oxidative stress, vascular calcification, and structural atrial remodeling. PCSK9 inhibitors such as alirocumab, evolocumab, and newer agents like inclisiran have shown potential in reducing AF incidence and cardiovascular events, particularly in high-risk populations. However, evidence from randomized controlled trials with AF as a primary clinical endpoint is limited. Further mechanistic and interventional research is warranted to establish optimized therapeutic strategies targeting PCSK9 in AF prevention and management.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sahebkar et al. (2026) conducted a review in Atrial fibrillation. PCSK9 and PCSK9 inhibitors (alirocumab, evolocumab, inclisiran) was evaluated on Atrial fibrillation incidence, progression, and related cardiovascular events. PCSK9 contributes to atrial fibrillation pathophysiology via inflammatory, oxidative, and remodeling pathways, though clinical evidence for PCSK9 inhibitors reducing AF remains hypothesis-generating.

synapsesocial.com/papers/6af0dba03c845ca7837cee0e https://doi.org/10.1155/cdr/7328020

View Full Paper

Ask AI

Bookmark

Share

PCSK9 and Atrial Fibrillation: A New Perspective on an Old Problem

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

PCSK9 and Atrial Fibrillation: A New Perspective on an Old Problem

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading